Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 1-(2-hydroxyethyl)-8-(5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy)anilino)-4,5-dihydropyrazolo(4,3-h)quinazoline-3-carboxamide
1. 1034616-18-6
2. Nms-1286937
3. Nms-p937
4. Onvansertib Free Base
5. Onvansertib [usan]
6. Nms-p937 (nms1286937)
7. Pcm-075
8. Nms1286937
9. 67rm91wdhq
10. Chembl1738758
11. Onvansertib (usan)
12. 1-(2-hydroxyethyl)-8-((5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy)phenyl)amino)-4,5-dihydro-1h-pyrazolo[4,3-h]quinazoline-3-carboxamide
13. 1-(2-hydroxyethyl)-8-[[5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy)phenyl]amino]-4,5-dihydropyrimido[5,4-g]indazole-3-carboxamide
14. 1-(2-hydroxyethyl)-8-[5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy)anilino]-4,5-dihydropyrazolo[4,3-h]quinazoline-3-carboxamide
15. Nms 1286937
16. 1h-pyrazolo(4,3-h)quinazoline-3-carboxamide, 4,5-dihydro-1-(2-hydroxyethyl)-8-((5-(4-methyl-1-piperazinyl)-2-(trifluoromethoxy)phenyl)amino)-
17. 1-(2-hydroxyethyl)-8-(5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy)anilino)-4,5-dihydropyrazolo(4,3-h)quinazoline-3-carboxamide
18. 1h-pyrazolo[4,3-h]quinazoline-3-carboxamide, 4,5-dihydro-1-(2-hydroxyethyl)-8-[[5-(4-methyl-1-piperazinyl)-2-(trifluoromethoxy)phenyl]amino]-;1h-pyrazolo[4,3-h]quinazoline-3-carboxamide, 4,5-dihydro-1-(2-hydroxyethyl)-8-[[5-(4-methyl-1-piperazinyl)-2-(trifluoromethoxy)phenyl]amino]-
19. Unii-67rm91wdhq
20. 1-(2-hydroxyethyl)-8-((5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy)phenyl)amino)-4,5-dihydro-1h-pyrazolo(4,3-h)quinazoline-3-carboxamide
21. Onvansertib [inn]
22. Onvansertib [who-dd]
23. Gtpl7918
24. Nms P937
25. Schembl1228019
26. Dtxsid701025917
27. Hms3653g04
28. Hms3673e21
29. Bcp28066
30. Ex-a1590
31. Bdbm50343559
32. Nsc781344
33. Nsc800806
34. S7255
35. Who 11172
36. Zinc43196885
37. Ccg-269924
38. Cs-3146
39. Db15110
40. Nsc-781344
41. Nsc-800806
42. Sb16941
43. Ncgc00386361-03
44. Ac-36303
45. Hy-15828
46. Nms-1286937,nms-p937
47. B4094
48. Sw219402-1
49. A13045
50. D11458
51. A896452
52. Polo-like Kinase 1 Inhibitor Nms-1286937
53. Q27087959
54. 1-(2-hydroxy-ethyl)-8-[5-(4-methyl-piperazin-1-yl)-2-trifluoromethoxy-phenylamino]-4,5-dihydro-1h-pyrazolo[4,3-h]quinazoline-3-carboxamide
55. 1-(2-hydroxyethyl)-8-(5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy)phenylamino)-4,5-dihydro-1h-pyrazolo[4,3-h]quinazoline-3-carboxamide
56. 1-(2-hydroxyethyl)-8-{[5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy)phenyl]amino}-1h,4h,5h-pyrazolo[4,3-h]quinazoline-3-carboxamide
| Molecular Weight | 532.5 g/mol |
|---|---|
| Molecular Formula | C24H27F3N8O3 |
| XLogP3 | 2 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 12 |
| Rotatable Bond Count | 7 |
| Exact Mass | 532.21582124 g/mol |
| Monoisotopic Mass | 532.21582124 g/mol |
| Topological Polar Surface Area | 135 Ų |
| Heavy Atom Count | 38 |
| Formal Charge | 0 |
| Complexity | 817 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Protein Kinase Inhibitors
Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Onvansertib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Onvansertib, including repackagers and relabelers. The FDA regulates Onvansertib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Onvansertib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Onvansertib supplier is an individual or a company that provides Onvansertib active pharmaceutical ingredient (API) or Onvansertib finished formulations upon request. The Onvansertib suppliers may include Onvansertib API manufacturers, exporters, distributors and traders.
Onvansertib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Onvansertib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Onvansertib GMP manufacturer or Onvansertib GMP API supplier for your needs.
A Onvansertib CoA (Certificate of Analysis) is a formal document that attests to Onvansertib's compliance with Onvansertib specifications and serves as a tool for batch-level quality control.
Onvansertib CoA mostly includes findings from lab analyses of a specific batch. For each Onvansertib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Onvansertib may be tested according to a variety of international standards, such as European Pharmacopoeia (Onvansertib EP), Onvansertib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Onvansertib USP).
LOOKING FOR A SUPPLIER?
